Latest Medical Devices News

Page 1 of 67
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
ReNerve has converted Indian regulatory approval into its first commercial NervAlign Nerve Cuff procedure, with a Bangalore patient treated for an upper-extremity nerve repair. The milestone arrives after record quarterly sales of $584,000 and expands the company’s Asia-Pacific rollout.
Victor Sage
Victor Sage
17 Nov 2026
Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
Victor Sage
Victor Sage
17 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
Nanosonics has secured a second US FDA 510(k) clearance for its CORIS System, expanding the range of colonoscopes and gastroscopes eligible for reprocessing. The regulatory milestone supports planned US launch activities, although the company has not disclosed a launch date or financial forecast.
Ada Torres
Ada Torres
11 Nov 2026
Uscom Limited (ASX:UCM) reported no customer receipts and just A$2,000 in cash at 30 September, as the former medical-device business moves into a minimal-activity phase. The company is now seeking an acquisition and a possible strategic relisting.
Ada Torres
Ada Torres
11 Nov 2026
Anteris Technologies reported a wider third-quarter loss as spending accelerated on its PARADIGM heart-valve trial and manufacturing expansion. The company ended September with US$236.3 million in cash, but also retained unresolved weaknesses in financial reporting controls.
Ada Torres
Ada Torres
11 Nov 2026
EBR Systems delivered higher reimbursement, manufacturing and revenue milestones in the third quarter, but a sharp September slowdown and a formal going-concern warning have shifted attention to execution and funding. The company says it holds US$93.2 million in cash, cash equivalents and marketable securities, while US$41.8 million of debt falls due within 12 months.
Victor Sage
Victor Sage
10 Nov 2026
BTC Health has expanded its exclusive ExoVasc PEARS distribution rights from Australia into India under a new five-year agreement. The opportunity is potentially significant, but Indian sales remain dependent on CDSCO import approval.
Ada Torres
Ada Torres
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
US Medicare has set a national outpatient payment of US$31,265 for Epiminder’s Minder System implant procedure from 1 January 2027, up 13% on the 2026 rate. The decision gives hospitals a defined reimbursement benchmark ahead of Epiminder’s planned US commercial launch.
Ada Torres
Ada Torres
6 Nov 2026
AVITA Medical has raised its 2026 revenue guidance for a second time after third-quarter revenue climbed 53% year on year. The company also drew a further US$10 million under its credit facility and removed its going-concern qualification, although it remains loss-making and highly leveraged.
Victor Sage
Victor Sage
6 Nov 2026

Browse the archive

Full archive